Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology
Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology
Unit 3
Unit 3
Notes
| DPP4 INHIBITORS | ||
| DRUG NAME | sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina, Vipidia) (Suffix: -gliptin) | |
| CLASS | DPP4 inhibitors | |
| MECHANISM OF ACTION | Increase the level of incretin hormones → increase insulin secretion, decrease glucagon secretion → reduce glucose production by the liver | |
| INDICATIONS | Type 2 diabetes mellitus | |
| ROUTE(S) OF ADMINISTRATION | PO | |
| SIDE EFFECTS |
| |
| CONTRAINDICATIONS AND CAUTIONS |
| |
| NURSING CONSIDERATIONS: DPP4 INHIBITORS | ||
| ASSESSMENT AND MONITORING | Assess
Monitor
Evaluate
| |
| CLIENT EDUCATION |
| |
Transcript
Dipeptidyl peptidase-4 inhibitors, or DPP4 inhibitors for short, are medications used to treat type 2 diabetes mellitus. Type 2 diabetes mellitus is characterized by insulin resistance, which is when tissue cells have trouble responding to insulin in order to use glucose from the blood.
As a result, tissue cells starve for energy despite having high blood glucose levels, which is called hyperglycemia. Now, commonly used DPP4 inhibitors are sitagliptin, saxagliptin, linagliptin, and alogliptin. All of them end with the suffix -gliptin, which makes them easy to recognize!
DPP4 inhibitors are taken orally. Once administered, these medications inhibit the enzyme DPP4, which normally destroys the hormone incretin.
As a result, DPP4 inhibitors increase the levels of incretin, which in turn increases insulin secretion and decreases glucagon secretion. The end result is a reduction in glucose production by the liver, and thus a reduction in blood glucose levels.
Now, the most common side effects of DPP4 inhibitors include headaches, nausea, vomiting, and diarrhea or constipation, as well as mild infections of the upper respiratory or urinary tract.
In addition, they can increase the risk of hypoglycemia, pancreatitis, and acute renal failure. Less frequently, DPP4 inhibitors can cause life-threatening side effects, such as anaphylaxis, angioedema or Stevens Johnson syndrome.
As far as contraindications go, DPP4 inhibitors should not be used in clients with a history of pancreatitis, hypoglycemia, and angioedema.
They should also be avoided in clients with a history of diabetic ketoacidosis, or DKA for short, which is an acute life-threatening complication of diabetes.
Finally, precautions should be taken during pregnancy and breastfeeding, as well as in elderly clients, and those with other endocrine, hepatic, or renal disorders.
Now, if a client with type 2 diabetes is prescribed a DPP4 inhibitor like sitagliptin, be sure to review their most recent laboratory test results, including blood glucose, hemoglobin A1c, as well as their renal and hepatic function.
Next, explain how the medication works to lower their blood glucose level. Be sure to remind them that the medication is most effective when combined with an antidiabetic regimen, which includes following a low-carbohydrate and high-fiber diet, regular physical activity, and frequent blood glucose monitoring.
Sources
- "Focus on Nursing Pharmacology" LWW (2019)
- "Pharmacology: A patient-centered nursing process approach" Elsevier Health Sciences (2014)
- "Mosby's 2021 Nursing Drug Reference" Mosby (2021)
- "Saunders Comprehensive Review for the NCLEX-RN Examination" Saunders (2020)
- "Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13e)" McGraw-Hill Education (2018)
- "Lehne's Pharmacology for Nursing Care" Saunders (2019)